Jacob Chacko - 17 Jun 2026 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Reporting relationship: Director
Issuer ticker: FDMT
Reported as of: 17 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2026, 17:28:46 UTC
Prior SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Scott Bizily as Attorney-in-Fact for Jacob Chacko

Key filing fact

Jacob Chacko filed Form 4 for 4D Molecular Therapeutics, Inc. (FDMT) on 18 Jun 2026.

Key facts

This page summarizes Jacob Chacko's Form 4 filing for 4D Molecular Therapeutics, Inc. (FDMT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2026, 17:28.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001608936 Primary reporting owner

Chacko Jacob

Relationship: Director
Address: C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE
Signature: /s/ Scott Bizily as Attorney-in-Fact for Jacob Chacko
Signature date: 18 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FDMT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +50,000
Change %
Price: $0.000000^*
Shares after: 50,000
Date: 17 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $9.42
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

Footnote F2

The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).